Association of genetic variants with chronic kidney disease in Japanese individuals with type 2 diabetes mellitus

International Journal of Molecular Medicine

Volumn 23, Issue 4, 2009, Pages 529-537

  Yoshida, Tetsuro ^a   Kato, Kimihiko ^b   Yokoi, Kiyoshi ^b   Watanabe, Sachiro ^c   Metoki, Norifumi ^d   Yoshida, Hidemi ^d   Satoh, Kei ^d   Aoyagi, Yukitoshi ^e   Nishigaki, Yutaka ^e   Suzuki, Takao ^e   Nozawa, Yoshinori ^f   Yamada, Yoshiji ^g  

^a Inabe General Hospital   (Japan)

^b GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^c GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^f GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^g MIE UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; End stage renal disease; Genetics; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BLOOD CLOTTING FACTOR 7; CATECHOL METHYLTRANSFERASE; CD31 ANTIGEN; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA 1; CYTOCHROME P450 3A4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL BETA SUBUNIT; MENADIONE EPOXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 1; RESERPINE; SREBF CLEAVAGE ACTIVATING PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; JAPAN; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67649419050     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000161     Document Type: Article

References (38)

1. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
2. Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004.
3. Ninomiya T, Kiyohara Y, Kubo M, et al: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68: 228-236, 2005.
4. Anavekar NS, McMurray JJ, Velazquez EJ, et al: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
5. Weiner DE, Tighiouart H, Stark PC, et al: Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 44: 198-206, 2004.
6. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y and Takishita S: Influence of smoking and obesity on the development of proteinuria. Kidney Int 62: 956-962, 2002.
7. de Jong PE and Brenner BM: From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 66: 2109-2118, 2004.
8. Iseki K, Oshiro S, Tozawa M, Ikemiya Y, Fukiyama K and Takishita S: Prevalence and correlates of diabetes mellitus in a screened cohort in Okinawa, Japan. Hypertens Res 25: 185-190, 2002.
9. Muntner P, Coresh J, Smith JC, Eckfeldt J and Klag MJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58: 293-301, 2000.
10. Kovesdy CP, Sharma K and Kalantar-Zadeh K: Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis 52: 766-777, 2008.
11. Kikkawa R, Togawa M, Isono M, Isshiki K and Haneda M: Mechanism of the progression of diabetic nephropathy to renal failure. Kidney Int 62 (Suppl): S39-S40, 1997.
12. Valmadrid CT, Klein R, Moss SE and Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160: 1093-1100, 2000.
13. Imai E, Matsuo S, Makino H, et al: Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 31: 1101-1107, 2008.
14. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1): S1-S266, 2002.
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 21: S5-S19, 1998.
16. Kuzuya T, Nakagawa S, Satoh J, et al: Report of the Committee on the Classification and Diagnosis Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 55: 65-85, 2002.
17. Itoh Y, Mizuki N, Shimada T, et al: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 57: 717-729, 2005.
18. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 57: 289-300, 1995.
19. Dixon RA, Diehl RE, Opas E, et al: Requirement of a 5- lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282-284, 1990.
20. Mehrabian M, Allayee H, Wong J, et al: Identification of 5- lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91: 120-126, 2002.
21. Brezinski DA, Nesto RW and Serhan CN: Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86: 56-63, 1992.
22. Spanbroek R, Grabner R, Lotzer K, et al: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100: 1238-1243, 2003.
23. Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36: 233-239, 2004.
24. Lõhmussaar E, Gschwendtner A, Mueller JC, et al: ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36: 731-736, 2005.
25. Kajimoto K, Shioji K, Ishida C, et al: Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 69: 1029-1034, 2005.
26. Zhang D, Sun M, Samols D and Kushner I: STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 271: 9503-9509, 1996.
27. Satterthwaite G, Francis SE, Suvarna K, et al: Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am Heart J 150: 488-499, 2005.
28. Huang Y, Li T, Sane DC and Li L: IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279: 51697-51703, 2004.
29. Lakoski SG, Li L, Langefeld CD, et al: The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp Mol Pathol 82: 280-283, 2007.
30. Yamada Y, Metoki N, Yoshida H, et al: Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 39: 2211-2218, 2008.
31. Lowe JB, Sacchettini JC, Laposata M, McQuillan JJ and Gordon JI: Expression of rat intestinal fatty acid-binding protein in Escherichia coli. Purification and comparison of ligand binding characteristics with that of Escherichia coli-derived rat liver fatty acid-binding protein. J Biol Chem 262: 5931-5937, 1987.
32. Baier LJ, Sacchettini JC, Knowler WC, et al: An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 95: 1281-1287, 1995.
33. Yamada K, Yuan X, Ishiyama S, et al: Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 40: 706-710, 1997.
34. Galluzzi JR, Cupples LA, Otvos JD, Wilson PW, Schaefer EJ and Ordovas JM: Association of the A/T54 polymorphism in the intestinal fatty acid binding protein with variations in plasma lipids in the Framingham Offspring Study. Atherosclerosis 159: 417-424, 2001.
35. Guettier JM, Georgopoulos A, Tsai MY, et al: Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 90: 1705-1711, 2005.
36. Yamada Y, Kato K, Oguri M, et al: Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 21: 801-808, 2008.
37. Carlsson M, Orho-Melander M, Hedenbro J, Almgren P and Groop LC: The T 54 allele of the intestinal fatty acid-binding protein 2 is associated with a parental history of stroke. J Clin Endocrinol Metab 85: 2801-2804, 2000.
38. Georgopoulos A, Bloomfield H, Collins D, et al: Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). Atherosclerosis 194: 169-174, 2007.